Compare GRAB & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRAB | PODD |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1B | 22.1B |
| IPO Year | N/A | 2007 |
| Metric | GRAB | PODD |
|---|---|---|
| Price | $5.13 | $288.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | $6.38 | ★ $366.58 |
| AVG Volume (30 Days) | ★ 35.5M | 706.4K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.02 | ★ 3.45 |
| Revenue | ★ $3,228,000,000.00 | $2,521,800,000.00 |
| Revenue This Year | $23.99 | $32.55 |
| Revenue Next Year | $21.71 | $20.39 |
| P/E Ratio | $255.35 | ★ $83.70 |
| Revenue Growth | 20.18 | ★ 27.11 |
| 52 Week Low | $3.36 | $230.05 |
| 52 Week High | $6.62 | $354.88 |
| Indicator | GRAB | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 37.94 |
| Support Level | $4.85 | $285.02 |
| Resistance Level | $5.28 | $292.75 |
| Average True Range (ATR) | 0.15 | 7.73 |
| MACD | 0.02 | -0.52 |
| Stochastic Oscillator | 56.00 | 12.27 |
Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore, Indonesia, and Malaysia contributed more than 70% of revenue in 2024. Grab's main competitors in Southeast Asia are Line Man and Goto. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.